Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion

Author:

Rudek Michelle A1,Bauer Kenneth S2,Lush Richard M3,Stinson Sherman F4,Senderowicz Adrian M5,Headlee Donna J6,Arbuck Susan G7,Cox Michael C8,Murgo Anthony J9,Sausville Edward A10,Figg William D11

Affiliation:

1. Michelle A Rudek PharmD PhD, at time of writing, BS, Pre-doctoral Fellow, Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD; now, Research Associate, Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

2. Kenneth S Bauer Jr PharmD PhD, at time of writing, Fellow, Clinical Pharmacology Research Core, National Cancer Institute; now, Assistant Professor, Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore

3. Richard M Lush III PhD, at time of writing, Fellow, Clinical Pharmacology Research Core, National Cancer Institute; now, Director, Clinical Research Unit, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

4. Sherman F Stinson PhD, Senior Scientist, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute at Frederick, Frederick, MD

5. Adrian M Senderowicz MD, at time of writing, Coordinator, Developmental Therapeutics Program, Clinical Trials Unit, National Cancer Institute; now, Chief, Molecular Therapeutics Unit, Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, Bethesda

6. Donna J Headlee RN, Research Nurse, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute

7. Susan G Arbuck MD, at time of writing, Section Chief, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute; now, Vice President and Global Head, Oncology Therapeutic Area, Aventis Pharmaceuticals, Bridgewater, NJ

8. Michael C Cox PharmD, Clinical Fellow, Clinical Pharmacology Research Core, National Cancer Institute

9. Anthony J Murgo MD, Senior Investigator, Investigational Drug Branch, Cancer Therapy and Evaluation Program, National Cancer Institute

10. Edward A Sausville MD PhD, Associate Director, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute

11. William D Figg PharmD, Senior Investigator, Head, Molecular Pharmacology Section, Cancer Therapeutics Branch; Head, Clinical Pharmacology Research Core, Medical Oncology Clinical Research Unit, National Cancer Institute

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3